Wednesday, October 14, 2026

How We Source Explore Search

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

News articleCB Insights

CEO Interview: LARX

View original at cbinsights.com

CB Insights - Enterprise Ai Title: CEO Interview: LARX Date: 2026-09-24 19:26 Source: https://www.cbinsights.com/research/ceo-interview-larx/ <h4><strong><a href="https://app.cbinsights.com/profiles/p/vl4gq/Current">Tad Mielnicki</a>, Chief Executive Officer (CEO) of <a href="https://app.cbinsights.com/profiles/c/ezY8b…

Opening lines of the source · CB Insights · short snapshot — read the full document at the original

Cited in these Via News reports

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe

October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,375 source documents archived

Query this data → isubstrate.com